Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.8K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

737
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
737
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.7K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients.

Blood advances·2026
Same author

Hematology in times of crisis: Lessons learned and strategic priorities from the EHA-ASH Joint Workshop on Ukraine.

HemaSphere·2026
Same author

Harnessing intermediate-scale bioreactors for next-generation macrophage production and application.

Nature protocols·2026
Same author

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Blood·2026
Same author

Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT.

Bone marrow transplantation·2025
Same author

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Leukemia·2025
Same journal

Unveiling the post translational modification code in Alzheimer's pathogenesis: crosstalk between phosphorylation and acetylation.

Expert review of proteomics·2026
Same journal

Plasma proteome profiles of standard-risk and high-risk childhood acute lymphoblastic leukemia.

Expert review of proteomics·2026
Same journal

Potential proteomic biomarkers for monitoring clinical studies in Duchenne/Becker muscular dystrophy.

Expert review of proteomics·2026
Same journal

Proteomics-based approaches to neutrophil biology.

Expert review of proteomics·2026
Same journal

Deciphering mitochondrial metabolic vulnerabilities in ovarian clear cell carcinoma with mass spectrometry-based clinical proteomics.

Expert review of proteomics·2026
Same journal

The proteomic origin of the genetic code.

Expert review of proteomics·2026
See all related articles

Related Experiment Video

Updated: Dec 25, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.6K

Proteomics for hematopoietic stem cell transplantation.

Eva M Weissinger1, Debora Basílio-Queirós1, Jochen Metzger2

  • 1Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Expert Review of Proteomics
|April 2, 2020
PubMed
Summary
This summary is machine-generated.

Proteomics analysis aids in diagnosing graft-versus-host disease (GvHD) after stem cell transplants. Enzyme-linked-immunosorbent assays (ELISA) and capillary electrophoresis-mass spectrometry (CE-MS) show promise for predicting and diagnosing GvHD.

Keywords:
Clinical proteomicsbiomarkersgraft-versus-host diseasestem cell transplantation

More Related Videos

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.8K
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.7K

Related Experiment Videos

Last Updated: Dec 25, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.6K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.8K
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.7K

Area of Science:

  • Proteomics and clinical diagnostics
  • Biomarker discovery in transplantation medicine

Background:

  • Proteomics analysis is crucial for understanding health and disease states.
  • High-throughput proteomic methods are vital for diagnosing complications post-allogeneic hematopoietic stem cell transplantation (HSCT).
  • Graft-versus-host disease (GvHD) prediction and diagnosis are key challenges in HSCT.

Purpose of the Study:

  • To review and compare two high-throughput proteomics technologies for GvHD assessment.
  • To discuss the strengths and limitations of ELISA and CE-MS in the clinical setting.
  • To evaluate the utility of these methods for predicting and diagnosing acute GvHD post-HSCT.

Main Methods:

  • Review of enzyme-linked-immunosorbent assays (ELISA) for key GvHD-associated proteins.
  • Review of capillary electrophoresis coupled on-line to mass spectrometry (CE-MS) for proteomic analysis.
  • Analysis of clinical data from patients undergoing HSCT.

Main Results:

  • Both ELISA and CE-MS are established high-throughput proteomics technologies used in clinical settings.
  • These methods have been applied to hundreds of patients post-HSCT.
  • Data generated by both technologies may offer complementary insights for GvHD diagnosis.

Conclusions:

  • ELISA and CE-MS are valuable tools in the post-HSCT clinical setting for GvHD assessment.
  • Further integration of data from these complementary proteomic approaches can enhance GvHD diagnosis.
  • These technologies hold significant potential for improving patient outcomes after HSCT.